Is Sermorelin Legal in Ohio?
Key numbers
- 0.5 mgStrength of the original Geref vials, approved for idiopathic growth hormone deficiency in children with growth failureSource: federalregister.gov, as cited Nov 7, 2026
- 30 micrograms per kgDose used in a historical pediatric growth hormone study; not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 14 daysLength of a historical study of 0.5 mg or 1 mg doses in older men; not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Sermorelin
At a glance
- Federal status / No FDA-approved sermorelin product; Geref's approvals ended June 18, 2009 [1]
- How it is sold now / Compounded only; compounded drugs are not FDA-approved [2]
- Approved uses (historic) / Test of pituitary growth hormone release; pediatric growth hormone deficiency [1]
- Adult anti-aging, weight loss, athletics / Never approved for these uses [1]
- FDA safety-risk list / Sermorelin does not appear on it (page dated 04/22/2026) [3]
- Outsourcing-facility bulk list / Category 1, under evaluation (list updated March 21, 2025) [4]
- Sport / Prohibited at all times by WADA, code S2.2.4 [5]
- Ohio / The Ohio Board of Pharmacy enforces state pharmacy and drug-distribution law; no Ohio rule on sermorelin is cited here [6]
Start With the Federal Record
Sermorelin acetate reached the US market as Geref under two approvals. NDA 019863 covered a 0.05 mg/ampule product approved December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone; NDA 020443 covered 0.5 mg and 1 mg vials approved September 26, 1997 for treating idiopathic growth hormone deficiency in children with growth failure [1].
The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications, and approval ended effective June 18, 2009 [1]. Those two uses were the only ones ever approved: Geref was not approved for adults, anti-aging, weight loss or athletic performance [1].
The exit was not a safety action. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [1][7]. With no approved product left, sermorelin sold in the US today is compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [2].
Where Sermorelin Sits on the FDA Compounding Lists
The federal lists that shape peptide compounding each treat sermorelin differently.
- FDA's list of bulk substances that may present significant safety risks (category 2), content dated 04/22/2026, does not include sermorelin [3].
- FDA's list of nominated bulk substances for outsourcing facilities, updated March 21, 2025, places sermorelin acetate in category 1, under evaluation, with the list's symbol for substances that are components of FDA-approved drugs [4].
- FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, does not place sermorelin in any category [8], and sermorelin is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9].
Ohio
The Ohio Board of Pharmacy describes itself as the single state agency responsible for administering and enforcing the state's pharmacy laws and the legal distribution of drugs [6]. Its general description does not mention sermorelin or peptides. The firm part of the picture is federal: there is no approved sermorelin product, and what is available is compounded [2].
Questions worth asking
Prescription Status Does Not Cover Sport
A separate rule applies to competition. WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, and prohibits it at all times, in and out of competition; S2 substances are non-Specified Substances [5]. The 2027 List, in force January 1, 2027, carries the same entry [10].
What the Drug Is, and What Doses Were Studied
Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone, not growth hormone itself; it acts on the pituitary to prompt release of the body's own growth hormone [11].
With no approved product there is no current approved dose. The historical studies used 30 micrograms per kg once daily subcutaneously at bedtime in the pediatric growth hormone deficiency program, and 0.5 mg or 1 mg subcutaneously twice daily for 14 days in a study of older men [12][13]. Neither figure is a recommended dose.
Frequently asked questions
Is sermorelin legal in Ohio?
Was sermorelin ever FDA-approved?
Why did Geref leave the market?
Is compounded sermorelin FDA-approved?
Where does sermorelin appear on the FDA compounding lists?
Does WADA prohibit sermorelin?
References
Show all 13 referencesHide references
- Federal Register :: Request Access.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Ohio Board of Pharmacy.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.